结肠直肠癌的临床病理学和分子特征在80岁以上的患者中
Renjie Luo1,2,3, Xiangchao Shi1,2,3, Zimin Zhao1,2,3
1Department of General Surgery, Peking University Third Hospital, Beijing, People's Republic of China.
Clinical interventions in aging
|December 10, 2025
概括
非常老的结肠直肠癌 (CRC) 患者 (≥80岁) 呈现出明显的临床和分子特征,包括较高的不匹配修复缺陷 (dMMR) 和较差的生存率. 这些发现支持为这个不断增长的人口提供个性化治疗.
科学领域:
- 在瘤学瘤学.
- 老年医学 老年医学
- 分子生物学分子生物学
背景情况:
- 全球人口老龄化正在增加老年人结直肠癌 (CRC) 的发病率.
- 非常老年CRC患者 (≥80岁) 的临床和分子特征尚不清楚.
- 这种差距阻碍了为这一群体制定有效的个性化治疗策略.
研究的目的:
- 系统地比较60-80岁的CRC患者的临床和分子形状,与80岁以上的CRC患者进行比较.
- 为了确定可能为非常老年CRC人口提供个性化治疗方法的独特特征.
- 提供基于证据的见解,了解晚年CRC的独特生物学.
主要方法:
- 对1172名接受了彻底手术的CRC患者进行了回顾性分析.
- 分类为老年人群 (≥80岁) 和年轻人群 (≥60岁和<80岁).
- 从初级CRC组织中对临床病理特征,无病生存率 (DFS) 和转录组测序数据的比较分析.
主要成果:
- 80岁以上的组显示化疗使用减少,CEA升高,更多的右侧和粘膜瘤,更大的尺寸和更高的不匹配修复缺陷 (dMMR) 患病率.
- 无病生存期 (DFS) 在≥80岁组显著较短,年龄≥80岁是一个独立的风险因素.
- 转录组分析显示,神经调节和细胞外基质重塑的调高,通过M2巨细胞透降低免疫力,并在老年人群中丰富CMS1/CMS4亚型.
结论:
- 80岁以上的CRC患者出现了较高的dMMR率和较短的DFS.
- 独特的分子特征包括免疫抑制,ECM重塑和增强的神经与瘤相互作用.
- 这些发现挑战了缓慢进展的假设,并支持对非常老的CRC患者进行个性化治疗.
相关概念视频
Tumor Progression
7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
181
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
181
Pharmacodynamics in Geriatric Patients: Effects of Age
175
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
175
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
217
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
217
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
215
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
215


